{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:21:28Z","timestamp":1788351688696,"version":"build-2803163510"},"reference-count":57,"publisher":"American Chemical Society (ACS)","issue":"25","license":[{"start":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T00:00:00Z","timestamp":1592524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/pubs.acs.org\/page\/policy\/authorchoice_termsofuse.html"}],"funder":[{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology","doi-asserted-by":"publisher","award":["DST\/AORC\u2013IF\/UPGRD\/IF160130"],"award-info":[{"award-number":["DST\/AORC\u2013IF\/UPGRD\/IF160130"]}],"id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>New organometallic drug candidates [Ph2Sn(HL)], 1, and [Ru(\u03b76--p-cymene)(HL)Cl], 2, were designed and synthesized by in situ reaction of a Schiff base ligand (HL) and diphenyltin dichloride and [RuCl2(p-cymene)]2, respectively. The drug candidates 1 and 2 have been characterized by spectroscopic methods (Fourier-transform infrared spectroscopy, UV\u2013vis, and 1H\/13C NMR), elemental analysis, and single X-ray crystallographic studies (in case of 1). The ground-state geometry optimization of 1 and 2 was performed by density functional theory calculations. The interaction of 1 and 2 with tRNA was assessed by absorption spectroscopy, cyclic voltammetry, circular dichroism, and ethidium bromide displacement assay using fluorescence emission spectroscopy to determine their potential to act as antitumor agents. The cytotoxicity of 1 and 2 was screened against human liver carcinoma (Huh7), prostate cancer (Du145), and the normal prostate cell line (PNT 2). The results implicated a dose-dependent growth inhibition of the two cancer cells at concentrations (2.5\u201315 \u03bcM) of 1 and 2 with the treatment after 48 h. Interestingly, 1 revealed good selective activity toward the liver cancer cell line (Huh7). Furthermore, both the drug candidates 1 and 2 were found to be nontoxic toward the PNT 2 normal cell line. These studies lay a paradigm for rational efficacious drug design for chemotherapeutic intervention in cancers using new tailored organometallic drug entities; organotin(IV) and organoruthenium(II) have been demonstrated to be viable for the safe administration and specific targeted drug uptake by the resistant cancerous cell lines at low intracellular concentrations.<\/jats:p>","DOI":"10.1021\/acsomega.0c01206","type":"journal-article","created":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T09:45:32Z","timestamp":1592559932000},"page":"15218-15228","source":"Crossref","is-referenced-by-count":24,"title":["New Tailored RNA-Targeted Organometallic Drug Candidates\nagainst Huh7 (Liver) and Du145 (Prostate) Cancer Cell Lines"],"prefix":"10.1021","volume":"5","author":[{"given":"Huzaifa Yasir","family":"Khan","sequence":"first","affiliation":[{"name":"Aligarh Muslim University , , ,","place":["Aligarh, India, 202002"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh K.","family":"Maurya","sequence":"additional","affiliation":[{"name":"Aligarh Muslim University , , ,","place":["Aligarh, India, 202002"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hifzur R.","family":"Siddique","sequence":"additional","affiliation":[{"name":"Aligarh Muslim University , , ,","place":["Aligarh, India, 202002"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shariq","family":"Yousuf","sequence":"additional","affiliation":[{"name":"Aligarh Muslim University , , ,","place":["Aligarh, India, 202002"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4677-2682","authenticated-orcid":true,"given":"Farukh","family":"Arjmand","sequence":"additional","affiliation":[{"name":"Aligarh Muslim University , , ,","place":["Aligarh, India, 202002"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2020,6,19]]},"reference":[{"key":"2026090207592079800_cit1","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/aoc.331","article-title":"Review: Organotin\ncompounds and their therapeutic potential: a report from the Organometallic\nChemistry Department of the Free University of Brussels","volume":"16","author":"Gielen","year":"2002","journal-title":"Appl. Organomet. Chem."},{"key":"2026090207592079800_cit2","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.drudis.2009.02.002","article-title":"Organometallic\ncompounds in oncology: implications of novel organotins as antitumor\nagents","volume":"14","author":"Alama","year":"2009","journal-title":"Drug Discovery Today"},{"key":"2026090207592079800_cit3","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.ejmech.2019.04.062","article-title":"Development and future\nprospects\nof selective organometallic compounds as anticancer drug candidates\nexhibiting novel modes of action","volume":"175","author":"Parveen","year":"2019","journal-title":"Eur. J. Med.\nChem."},{"key":"2026090207592079800_cit4","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/jat.1290","article-title":"Cell proliferation\ninhibition and\nantitumor activity of novel alkyl series of diorganotin (IV) compounds","volume":"28","author":"Koch","year":"2008","journal-title":"J. Appl. Toxicol."},{"key":"2026090207592079800_cit5","doi-asserted-by":"publisher","first-page":"3687","DOI":"10.1021\/ic302196v","article-title":"DNA binding\nand anti-cancer activity of redox-active heteroleptic piano-stool\nRu (II), Rh (III), and Ir (III) complexes containing 4-(2-methoxypyridyl)\nphenyldipyrromethene","volume":"52","author":"Gupta","year":"2013","journal-title":"Inorg. Chem."},{"key":"2026090207592079800_cit6","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1039\/c8ra07926a","article-title":"Scope of organometallic compounds\nbased on transition metal-arene systems as anticancer agents: starting\nfrom the classical paradigm to targeting multiple strategies","volume":"9","author":"Zaki","year":"2019","journal-title":"RSC Adv."},{"key":"2026090207592079800_cit7","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1016\/j.jorganchem.2005.12.033","article-title":"Chemical and\nbiotechnological developments in organotin\ncancer chemotherapy","volume":"691","author":"Tabassum","year":"2006","journal-title":"J. Organomet. Chem."},{"key":"2026090207592079800_cit8","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ica.2014.07.066","article-title":"Organo-tin\nantitumor compounds: Their present status in drug development and\nfuture perspectives","volume":"423","author":"Arjmand","year":"2014","journal-title":"Inorg. Chim. Acta"},{"key":"2026090207592079800_cit9","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.ccr.2007.12.026","article-title":"Antiproliferative\nand anti-tumor activity of organotin\ncompounds","volume":"253","author":"Hadjikakou","year":"2009","journal-title":"Coord. Chem. Rev."},{"key":"2026090207592079800_cit10","doi-asserted-by":"publisher","first-page":"119464","DOI":"10.1016\/j.ica.2020.119464","article-title":"Recent advancements\nin the anticancer potentials of phenylorganotin (IV) complexes","volume":"505","author":"Khan","year":"2020","journal-title":"Inorg. Chim. Acta"},{"key":"2026090207592079800_cit11a","doi-asserted-by":"publisher","first-page":"110154","DOI":"10.1016\/j.micromeso.2020.110154","article-title":"Mesoporous\nsilica nanoparticles functionalized with a dialkoxide diorganotin(IV)\ncompound: In search of more selective systems against cancer cells","volume":"300","author":"Di\u0301az-Garci\u0301a","year":"2020","journal-title":"Microporous Mesoporous Mater."},{"key":"2026090207592079800_cit11b","doi-asserted-by":"publisher","first-page":"12284","DOI":"10.1039\/c8dt01677a","article-title":"Modulation of the mechanism of apoptosis in cancer\ncell lines by treatment with silica-based nanostructured materials\nfunctionalized with different metallodrugs","volume":"47","author":"Di\u0301az-Garci\u0301a","year":"2018","journal-title":"Dalton Trans."},{"key":"2026090207592079800_cit12","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.jinorgbio.2007.04.002","article-title":"Synthesis and characterization of\ndi-phenyl-tinIV-salicyliden-ortho-aminophenols: Analysis of in vitro\nantitumor\/antioxidant activities and molecular structures","volume":"101","author":"Beltra\u0301n","year":"2007","journal-title":"J. Inorg. Biochem."},{"key":"2026090207592079800_cit13","doi-asserted-by":"publisher","first-page":"5771","DOI":"10.1039\/c7cs00195a","article-title":"The development of anticancer ruthenium\n(II) complexes: from single molecule compounds to nanomaterials","volume":"46","author":"Zeng","year":"2017","journal-title":"Chem. Soc. Rev."},{"key":"2026090207592079800_cit14a","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1021\/om500317b","article-title":"Ruthenium (II)\u2013arene\nRAPTA type complexes containing curcumin and bisdemethoxycurcumin\ndisplay potent and selective anticancer activity","volume":"33","author":"Pettinari","year":"2014","journal-title":"Organometallics"},{"key":"2026090207592079800_cit14b","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1039\/b104021a","article-title":"[Ru(\u03b76-p-cymene)Cl2(pta)](pta= 1, 3, 5-triaza-7-phosphatricyclo-[3.3.1.1]\ndecane): a water soluble compound that exhibits pH dependent DNA binding\nproviding selectivity for diseased cells","volume":"15","author":"Allardyce","year":"2001","journal-title":"Chem.\nCommun."},{"key":"2026090207592079800_cit15","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1038\/ncomms4462","article-title":"Ligand substitutions\nbetween ruthenium\u2013cymene compounds can control protein versus\nDNA targeting and anticancer activity","volume":"5","author":"Adhireksan","year":"2014","journal-title":"Nat.\nCommun."},{"key":"2026090207592079800_cit16","doi-asserted-by":"publisher","first-page":"692","DOI":"10.2533\/chimia.2007.692","article-title":"Ruthenium anticancer\ncompounds: challenges and expectations","volume":"61","author":"Bratsos","year":"2007","journal-title":"CHIMIA\nInt. J. Chem."},{"key":"2026090207592079800_cit16b","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/cad.0b013e328322fbc5","article-title":"Pharmacokinetics of a novel anticancer\nruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study","volume":"20","author":"Lentz","year":"2009","journal-title":"Anti-Cancer Drugs"},{"key":"2026090207592079800_cit16c","doi-asserted-by":"publisher","first-page":"7588","DOI":"10.1039\/b905798f","article-title":"A categorization of\nmetal anticancer compounds based on their mode of action","author":"Gianferrara","year":"2009","journal-title":"Dalton Trans."},{"key":"2026090207592079800_cit17a","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1021\/jm100020w","article-title":"Organometallic\nAnticancer Compounds","volume":"54","author":"Gasser","year":"2011","journal-title":"J. Med. Chem."},{"key":"2026090207592079800_cit17b","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1039\/b712656p","article-title":"Antitumour metal compounds: more than theme and variations","volume":"2","author":"Jakupec","year":"2008","journal-title":"Dalton Trans."},{"key":"2026090207592079800_cit17c","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1039\/b601840h","article-title":"Metal-based antitumour drugs in the\npost genomic era","volume":"16","author":"Dyson","year":"2006","journal-title":"Dalton Trans."},{"key":"2026090207592079800_cit17d","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/s0010-8545(02)00025-5","article-title":"Ruthenium metallopharmaceuticals","volume":"232","author":"Clarke","year":"2002","journal-title":"Coord. Chem. Rev."},{"key":"2026090207592079800_cit17e","doi-asserted-by":"publisher","first-page":"10793","DOI":"10.1039\/c1dt11007a","article-title":"Targeted and multifunctional arene\nruthenium chemotherapeutics","volume":"40","author":"Smith","year":"2011","journal-title":"Dalton Trans."},{"key":"2026090207592079800_cit18","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1021\/jm3000906","article-title":"A SAR study\nof novel antiproliferative ruthenium and osmium complexes with quinoxalinone\nligands in human cancer cell lines","volume":"55","author":"Ginzinger","year":"2012","journal-title":"J. Med.\nChem."},{"key":"2026090207592079800_cit19","doi-asserted-by":"publisher","first-page":"5475","DOI":"10.1039\/c9nj00042a","article-title":"Design and synthesis\nof a DNA intercalative half-sandwich organoruthenium (ii)\u2013chromone\ncomplex: cytotoxicity evaluation and topoisomerase I\u03b1 inhibition\nassay","volume":"43","author":"Yousuf","year":"2019","journal-title":"New J. Chem."},{"key":"2026090207592079800_cit20","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1021\/cr960415w","article-title":"A structural basis for RNA\u2013ligand interactions","volume":"97","author":"Chow","year":"1997","journal-title":"Chem. Rev."},{"key":"2026090207592079800_cit21","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.3390\/cancers11111652","article-title":"Role of Non-Coding\nRNAs in the Progression of Liver Cancer: Evidence from Experimental\nModels","volume":"11","author":"O\u2019Brien","year":"2019","journal-title":"Cancers"},{"key":"2026090207592079800_cit22","unstructured":"https:\/\/www.healthline.com\/health\/liver-metastases,17 \/09\/ 2018."},{"key":"2026090207592079800_cit23","unstructured":"https:\/\/www.cancer.net\/navigating-cancer-care\/how-cancer-treated\/personalized-and-targeted-therapies\/understanding-targeted-therapys, 05\/2020."},{"key":"2026090207592079800_cit24","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.molstruc.2011.02.003","article-title":"A new tetranuclear\ncopper (II) Schiff\nbase complex containing Cu4O4 cubane core: Structural\nand spectral characterizations","volume":"991","author":"Shit","year":"2011","journal-title":"J. Mol. Struct."},{"key":"2026090207592079800_cit25","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jorganchem.2014.02.010","article-title":"Homobimetallic organotin (IV) complexes\nwith hexadentate Schiff base: Synthesis, crystal structure and antimicrobial\nstudies","volume":"759","author":"Shujah","year":"2014","journal-title":"J. Organomet. Chem."},{"key":"2026090207592079800_cit26","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.molstruc.2016.07.079","article-title":"Synthesis and spectral\ncharacterization of 2-((2-hydroxybenzylidene)\namino)-2-methylpropane-1, 3-diol derived complexes: Molecular docking\nand antimicrobial studies","volume":"1127","author":"Ansari","year":"2017","journal-title":"J. Mol. Struct."},{"key":"2026090207592079800_cit27","doi-asserted-by":"publisher","first-page":"3714","DOI":"10.1016\/j.jorganchem.2005.04.049","article-title":"Synthesis, characterization\nand structural studies of diorganotin(IV) complexes with Schiff base\nligand salicylaldehyde isonicotinylhydrazone","volume":"690","author":"Yin","year":"2005","journal-title":"J. Organomet. Chem."},{"key":"2026090207592079800_cit28","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1021\/acs.organomet.5b00933","article-title":"Half-sandwich ruthenium complexes with Schiff-base\nligands: Syntheses, characterization, and catalytic activities for\nthe reduction of nitroarenes","volume":"35","author":"Jia","year":"2016","journal-title":"Organometallics"},{"key":"2026090207592079800_cit29","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1021\/acs.organomet.8b00004","article-title":"Water-soluble mono-and\nbinuclear Ru(\u03b76-p-cymene) complexes containing indole\nthiosemicarbazones: Synthesis, DFT modeling, biomolecular interactions,\nand in vitro anticancer activity through apoptosis","volume":"37","author":"Haribabu","year":"2018","journal-title":"Organometallics"},{"key":"2026090207592079800_cit30","doi-asserted-by":"publisher","first-page":"3836","DOI":"10.1016\/j.jorganchem.2011.08.007","article-title":"In vitro binding studies of organotin(IV)\ncomplexes of 1,2-bis(1H-benzimidazol-2-yl)ethane-1,2-diol with CT-DNA\nand nucleotides (5\u2019-GMP and 5\u2019-TMP): Effect of the ancillary\nligand on the binding propensity","volume":"696","author":"Arjmand","year":"2011","journal-title":"J. Organomet.\nChem."},{"key":"2026090207592079800_cit31","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jphotobiol.2014.04.024","article-title":"Design and synthesis of enantiomeric\n(R)-and (S)-copper (II) and diorganotin (IV)-based antitumor agents:\nTheir in vitro DNA binding profile, cleavage efficiency and cytotoxicity\nstudies","volume":"136","author":"Arjmand","year":"2014","journal-title":"J. Photochem. Photobiol., B"},{"key":"2026090207592079800_cit32","doi-asserted-by":"publisher","first-page":"45229","DOI":"10.1038\/srep45229","article-title":"Heteroleptic Copper (I) Complexes\nof \u201cScorpionate\u201d Bis-pyrazolyl Carboxylate Ligand with\nAuxiliary Phosphine as Potential Anticancer Agents: An Insight into\nCytotoxic Mode","volume":"7","author":"Khan","year":"2017","journal-title":"Sci. Rep."},{"key":"2026090207592079800_cit33","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jinorgbio.2014.01.011","article-title":"Synthesis,\nspectroscopic and DFT structural characterization of two novel ruthenium(III)\noxicam complexes. In vivo evaluation of anti-inflammatory and gastric\ndamaging activities","volume":"134","author":"Tamasi","year":"2014","journal-title":"J. Inorg. Biochem."},{"key":"2026090207592079800_cit34","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1002\/(sici)1521-3757(19990601)111:11&lt;1681::aid-ange1681&gt;3.0.co;2-6","article-title":"RNA and the\nsmall molecule World","volume":"111","author":"Tor","year":"1999","journal-title":"Angew. Chem."},{"key":"2026090207592079800_cit35","doi-asserted-by":"publisher","first-page":"7691","DOI":"10.1021\/acsomega.9b00131","article-title":"Enantiomeric\nAmino Acid Schiff Base\nCopper (II) Complexes as a New Class of RNA-Targeted Metallo-Intercalators:\nSingle X-Ray Crystal Structural Details, Comparative in Vitro DNA\/RNA\nBinding Profile, Cleavage, and Cytotoxicity","volume":"4","author":"Zehra","year":"2019","journal-title":"ACS Omega"},{"key":"2026090207592079800_cit36","doi-asserted-by":"publisher","first-page":"6392","DOI":"10.1021\/bi00394a013","article-title":"Polycyclic aromatic\nhydrocarbons physically intercalate into duplex regions of denatured\nDNA","volume":"26","author":"Wolfe","year":"1987","journal-title":"Biochemistry"},{"key":"2026090207592079800_cit37","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1071\/ch10178","article-title":"Nucleic Acid (Calf Thymus-DNA, Yeast tRNA) Binding\nand Cytotoxic Properties of a Dinuclear (Ru, Co) Metal Polypyridyl\nComplex","volume":"63","author":"Liang","year":"2010","journal-title":"Aust. J. Chem."},{"key":"2026090207592079800_cit38a","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1039\/c9ra07464c","article-title":"Evaluation\nof cytotoxic potential of structurally well-characterized RNA targeted\nionic non-steroidal anti-inflammatory (NSAID) Cu (II) & Zn (II)\nDACH\u2013mefenamato drug conjugates against human cancer cell lines","volume":"10","author":"Khan","year":"2020","journal-title":"RSC Adv."},{"key":"2026090207592079800_cit38b","doi-asserted-by":"publisher","first-page":"79372","DOI":"10.1039\/c6ra14503e","article-title":"Synthesis,\ncharacterization, and crystal structure of RNA targeted L- and D-phenylalanine-(1,10-phen)\u2013copper(II)\nconjugate complexes: comparative in vitro RNA binding profile of enantiomers\nand their biological evaluation by morphological studies andantibacterial\nactivity","volume":"6","author":"Sharma","year":"2016","journal-title":"RSC Adv."},{"key":"2026090207592079800_cit39","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1021\/ed084p1304","article-title":"Quantitative\nDetermination of DNA\u2013Ligand Binding Using Fluorescence Spectroscopy","volume":"84","author":"Hearly","year":"2007","journal-title":"J. Chem. Educ."},{"key":"2026090207592079800_cit40","doi-asserted-by":"publisher","first-page":"5732","DOI":"10.1093\/nar\/gkg758","article-title":"The DNA and\nRNA specificity of eilatin Ru(II) complexes as compared\nto eilatin and ethidium bromide","volume":"31","author":"Luedtke","year":"2003","journal-title":"Nucleic Acids\nRes."},{"key":"2026090207592079800_cit41","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1007\/s12010-018-2818-z","article-title":"Cyclic Voltammetric\nDNA Binding Investigations on Some\nAnticancer Potential Metal Complexes: a Review","volume":"186","author":"Arshad","year":"2018","journal-title":"Appl. Biochem. Biotechnol."},{"key":"2026090207592079800_cit42","doi-asserted-by":"publisher","first-page":"335","DOI":"10.2174\/1871520617666171106125114","article-title":"Recent Advancements in Organotin (IV) Complexes as Potential Anticancer\nAgents","volume":"18","author":"Devi","year":"2018","journal-title":"Anti-Cancer Agents Med. Chem."},{"key":"2026090207592079800_cit43","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/wcms.81","article-title":"The ORCA program\nsystem","volume":"2","author":"Neese","year":"2012","journal-title":"Wiley Interdiscip. Rev.: Comput. Mol.\nSci."},{"key":"2026090207592079800_cit44","unstructured":"Neese, F. O. R. C. A.\n          \n          An Ab Initio:\nDensity Functional and Semi-empirical Program Package\nversion, 2009."},{"key":"2026090207592079800_cit45","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1063\/1.463096","article-title":"Fully optimized contracted Gaussian\nbasis sets for atoms Li to Kr","volume":"97","author":"Scha\u0308fer","year":"1992","journal-title":"J. Chem. Phys."},{"key":"2026090207592079800_cit47","unstructured":"Sheldrick, G. M.\n          \n          SHELXT-97, Prog. Crystal-Structure Refinement, 1997."},{"key":"2026090207592079800_cit48","doi-asserted-by":"publisher","first-page":"W445","DOI":"10.1093\/nar\/gkq311","article-title":"HexServer:\nan FFT-based protein docking server powered by graphics processors","volume":"38","author":"Macindoe","year":"2010","journal-title":"Nucleic Acids Res."},{"key":"2026090207592079800_cit49","doi-asserted-by":"publisher","first-page":"5379","DOI":"10.1158\/1078-0432.ccr-11-0916","article-title":"A novel androgen receptor\ninhibitor: implications in prostate cancer therapy","volume":"17","author":"Siddique","year":"2011","journal-title":"Clin. Cancer Res."}],"container-title":["ACS Omega"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acsomega.0c01206","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/acsodf\/article-pdf\/5\/25\/15218\/67730953\/acsomega.0c01206.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/acsodf\/article-pdf\/5\/25\/15218\/67730953\/acsomega.0c01206.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:59:30Z","timestamp":1788350370000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/acsodf\/article\/5\/25\/15218\/975348\/New-Tailored-RNA-Targeted-Organometallic-Drug"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,19]]},"references-count":57,"journal-issue":{"issue":"25","published-online":{"date-parts":[[2020,6,19]]},"published-print":{"date-parts":[[2020,6,30]]}},"URL":"https:\/\/doi.org\/10.1021\/acsomega.0c01206","relation":{},"ISSN":["2470-1343"],"issn-type":[{"value":"2470-1343","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,19]]}}}